CAMK2D serves as a molecular scaffold for RNF8-MAD2 complex to induce mitotic checkpoint in glioma
You Heng Chuah,Emmy Xue Yun Tay,Oleg V. Grinchuk,Jeehyun Yoon,Jia Feng,Srinivasaraghavan Kannan,Matius Robert,Rekha Jakhar,Yajing Liang,Bernice Woon Li Lee,Loo Chien Wang,Yan Ting Lim,Tianyun Zhao,Radoslaw M. Sobota,Guang Lu,Boon Chuan Low,Karen Carmelina Crasta,Chandra Shekhar Verma,Zhewang Lin,Derrick Sek Tong Ong
DOI: https://doi.org/10.1038/s41418-023-01192-3
IF: 12.067
2023-01-01
Cell Death and Differentiation
Abstract:MAD2 is a spindle assembly checkpoint protein that participates in the formation of mitotic checkpoint complex, which blocks mitotic progression. RNF8, an established DNA damage response protein, has been implicated in mitotic checkpoint regulation but its exact role remains poorly understood. Here, RNF8 proximity proteomics uncovered a role of RNF8-MAD2 in generating the mitotic checkpoint signal. Specifically, RNF8 competes with a small pool of p31 comet for binding to the closed conformer of MAD2 via its RING domain, while CAMK2D serves as a molecular scaffold to concentrate the RNF8-MAD2 complex via transient/weak interactions between its p-Thr287 and RNF8’s FHA domain. Accordingly, RNF8 overexpression impairs glioma stem cell (GSC) mitotic progression in a FHA- and RING-dependent manner. Importantly, low RNF8 expression correlates with inferior glioma outcome and RNF8 overexpression impedes GSC tumorigenicity. Last, we identify PLK1 inhibitor that mimics RNF8 overexpression using a chemical biology approach, and demonstrate a PLK1/HSP90 inhibitor combination that synergistically reduces GSC proliferation and stemness. Thus, our study has unveiled a previously unrecognized CAMK2D-RNF8-MAD2 complex in regulating mitotic checkpoint with relevance to gliomas, which is therapeutically targetable.